SCHEMBL26075556

SCHEMBL26075556

CCCCCCCCOc1ccc(-c2ccc(-c3cc(CC)c4cc(F)ccc4n3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 4/20 0.50
▸ ESR1 P03372 2/20 0.48
▸ ESR2 Q92731 2/20 0.48
▸ ESRRB O95718 1/20 0.48
▸ ESRRA P11474 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ RARB P10826 3/20 0.46
▸ DHODH Q02127 4/20 0.46
▸ PDE10A Q9Y233 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ XDH P47989 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075537 1.00 PLA2G2A (0.50) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26075544 0.99 PLA2G2A (0.51) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26075536 0.97 PLA2G2A (0.53) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26075534 0.92 PDE10A (0.54) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26074014 0.88 PLA2G2A (0.48) PLA2G2AMAPTRARBDHODHPDE10A
SCHEMBL26074112 0.88 PLA2G2A (0.49) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26075529 0.87 ESR1 (0.53) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL26074127 0.87 ESR1 (0.48) PLA2G2AESR1ESR2ESRRBESRRA
SCHEMBL23590083 0.86 DHODH (0.64) PLA2G2ARARBDHODHPDE10AKDM4E
SCHEMBL23590074 0.86 DHODH (0.64) PLA2G2ARARBDHODHPDE10AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PLA2G2A 1679/4885ESR1 4427/4885ESR2 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback